
Investor interview - April 15, 2021
Eugen Steiner – The company doctor
Eugen Steiner has worked in venture capital for 23 years but his roots as a medical doctor still influence the way he nurtures start-ups as a venture partner. “My role as a venture partner [at HealthCap – a family of venture capital funds investing globally in life sciences] is like a company doctor. I deliver […]

Prio - June 11, 2020
Pharma industry confronts growing problem of pharmaceutical waste
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health. While pharmaceutical companies are stepping up their efforts to tackle the issue, watchdog organizations, the UN, the […]

Prio - June 18, 2019
Pharma industry confronts growing problem of pharmaceutical waste
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have devastating effects on both aquatic and human health.

Nobel Prize Laureate - December 20, 2018
Donna Strickland: “It’s all about the science”
Science has always been a driving force in Donna Strickland's life. From the moment she discovered the world of laser physics, she’s been entranced by all the possibilities lasers represent for research, science and medicine.

Nobel Prize Laureate - December 20, 2018
Gérard Mourou: The eureka moment
A passion for laser physics has been the guiding light for Gérard Mourou throughout his entire career. Even in 1957, he could see the limitless potential of this nascent field of science. What he didn’t envision then is that one day his discoveries would lead to winning the 2018 Nobel Prize in Physics.

Biotech article - January 1, 2013
Risky Business
Biotech is an industry with great promise — and great risk. Reaping the benefits of a promising new drug while sidestepping the quicksand of expensive, super-sized failures is no easy feat. In recent years, with a string of high-profile, late-stage drug failures, many venture capitalists jumped ship for safer waters. No one understands this better […]